Based on promising preclinical data [126,127,128], clinical studies are evaluating a combination of adenovirus-based therapy DNX-2401 with anti-PD-1 blockade for recurrent GBM (NCT02798406). The gene discussed is PDCD1; the disease is glioblastoma.